uniQure - QURE Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for uniQure in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" QURE shares.
View QURE analyst ratings or view top-rated stocks.

6 brokers have issued twelve-month price targets for uniQure's stock. Their QURE share price forecasts range from $24.00 to $65.00. On average, they expect the company's share price to reach $47.17 in the next year. This suggests a possible upside of 112.9% from the stock's current price.
View analysts price targets for QURE or view top-rated stocks among Wall Street analysts.

uniQure's stock was trading at $22.67 at the start of the year. Since then, QURE shares have decreased by 2.3% and is now trading at $22.15.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Friday, February 24th 2023.
View our QURE earnings forecast.

uniQure (NASDAQ:QURE) announced its quarterly earnings results on Sunday, October, 24th. The biotechnology company reported ($0.79) EPS for the quarter, beating analysts' consensus estimates of ($1.05) by $0.26. The biotechnology company earned $2 million during the quarter, compared to the consensus estimate of $2.13 million. uniQure had a negative trailing twelve-month return on equity of 24.47% and a negative net margin of 204.12%. The business's revenue for the quarter was up 11.1% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.21) earnings per share.

8 employees have rated uniQure Chief Executive Officer Matthew Kapusta on Glassdoor.com. Matthew Kapusta has an approval rating of 74% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other uniQure investors own include Empire Resorts (NYNY), Micron Technology (MU), Gilead Sciences (GILD), Alibaba Group (BABA), AbbVie (ABBV), GW Pharmaceuticals (GWPH), NVIDIA (NVDA), Exelixis (EXEL), Block (SQ) and bluebird bio (BLUE).

uniQure trades on the NASDAQ under the ticker symbol "QURE."

uniQure's stock is owned by a variety of retail and institutional investors. Top institutional investors include International Biotechnology Trust PLC (1.35%), Privium Fund Management B.V. (0.64%), Nordea Investment Management AB (0.61%), Banque Pictet & Cie SA (0.58%), China Universal Asset Management Co. Ltd. (0.28%) and UBS Group AG (0.27%). Insiders that own company stock include Alexander Edward Kuta III, Christian Klemt, Leonard E Post, Matthew C Kapusta, Paula Soteropoulos, Pierre Caloz, Ricardo Dolmetsch and Robert Gut.
View institutional ownership trends.

Shares of QURE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of QURE stock can currently be purchased for approximately $22.15.

uniQure (NASDAQ:QURE) has a market capitalization of $1.04 billion and generates $524 million in revenue each year. The biotechnology company earns $329.59 million in net income (profit) each year or ($2.69) on an earnings per share basis.

The company employs 463 workers across the globe.

uniQure's mailing address is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. The official website for the company is www.uniqure.com. The biotechnology company can be reached via phone at (120) 240-6000, via email at investors@uniqure, or via fax at 31-20-566-9272.